Kabra Drugs, a company in the Pharmaceuticals industry, reported revenue of ₹32 crore and net profit of ₹1.92 crore for the September 2026 quarter.
Kabra Drugs (BSE: KABRADG) closed at ₹18.89 on 20 Nov 2026, down 26.4% over the past year. Its market capitalisation is ₹45 crore and it trades at 5.8 times earnings.
Incorporated in 1989, Kabra Drugs Ltd deals in pharmaceutical products, biological API’s and biochemicals.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.